Scarica l'app Stockscreener
13.79
0.11%
-0.015
Dopo l'orario di chiusura:
13.79
0.005
+0.04%
Precedente Chiudi:
$13.80
Aprire:
$13.97
Volume 24 ore:
34,167
Relative Volume:
0.83
Capitalizzazione di mercato:
$349.47M
Reddito:
$59,000
Utile/perdita netta:
$-21.81M
Rapporto P/E:
-1.2587
EPS:
-10.9518
Flusso di cassa netto:
$-18.07M
1 W Prestazione:
+0.77%
1M Prestazione:
-14.43%
6M Prestazione:
+28.95%
1 anno Prestazione:
+105.13%
Intervallo 1D:
$13.38
$14.22
Intervallo di 1 settimana:
$13.26
$14.22
Portata 52W:
$5.742
$16.90
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Confronta BNTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
13.79 | 349.47M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
(BNTC) Long Term Investment Analysis - news.stocktradersdaily.com
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? - Yahoo Finance
Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha
JMP Securities Boosts Benitec Biopharma (NASDAQ:BNTC) Price Target to $20.00 - Defense World
Benitec Biopharma (BNTC) Stock Price Target Increased Amid Promi - GuruFocus
Benitec stock price target raised to $20 at JMP Securities - Investing.com Australia
Benitec stock price target raised to $20 at JMP Securities By Investing.com - Investing.com India
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Average Rating of “Buy” by Brokerages - Defense World
Q3 EPS Forecast for Benitec Biopharma Boosted by Analyst - Defense World
Suvretta capital management buys $211,736 in Benitec Biopharma shares By Investing.com - Investing.com Canada
Insiders Are Loving These 5 Tech and Biotech Stocks - 24/7 Wall St.
Discover the Top 5 Small-Cap Biotech Stocks in 2025 - Investing News Network
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 900,000 Shares of Stock - MarketBeat
Benitec Biopharma completes stock and warrant offerings By Investing.com - Investing.com Australia
Suvretta capital purchases $11.7m in Benitec Biopharma shares By Investing.com - Investing.com India
Major Investment Alert: Benitec Biopharma Stock Purchase Shakes the Market! - TipRanks
Benitec Biopharma completes stock and warrant offerings - Investing.com India
Suvretta capital purchases $11.7m in Benitec Biopharma shares - Investing.com
Benitec Biopharma inks deal granting stock resale rights - Investing.com India
Benitec Biopharma inks deal granting stock resale rights By Investing.com - Investing.com Canada
Benitec Biopharma prices $30M securities offerings - MSN
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewswire
Benitec Biopharma prices 1.44M shares at $13.00 in underwritten offering - TipRanks
Benitec Biopharma Prices $30 Million Equity Offerings - MarketScreener
(BNTC) Trading Report - news.stocktradersdaily.com
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
H.C. Wainwright maintains Buy on Benitec BioPharma stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on Benitec BioPharma stock - Investing.com
Micron Technology, Nike, FedEx And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 17.6% in February - Defense World
Benitec Biopharma stock soars to 52-week high of $16.2 By Investing.com - Investing.com Australia
Benitec Biopharma stock soars to 52-week high of $16.2 - Investing.com
Benitec reports progress in OPMD swallowing function study By Investing.com - Investing.com South Africa
Benitec Biopharma Reports Positive Interim Results For BB-301 Gene Therapy In OPMD Clinical Trial - RTTNews
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise in OPMD By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise in OPMD - Investing.com
Benitec Biopharma Announces Positive Interim Results for BB-301 - TipRanks
Benitec reports progress in OPMD swallowing function study - Investing.com India
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - The Manila Times
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with ... - The Bakersfield Californian
Benitec Biopharma Reports Positive Interim Clinical Results - GlobeNewswire
Benitec stock holds $18 target, Market Outperform rating By Investing.com - Investing.com UK
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Benitec Biopharma Inc Azioni (BNTC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):